Gilead Sciences
4 stories
-
healthWHO Raises Ebola Risk to 'Very High' in DR Congo
WHO upgrades Ebola risk in DR Congo to 'very high' amid rising cases, with 82 confirmed and nearly 750 suspected infections.
-
healthSeladelpar Emerges as Key PBC Therapy in Europe
Gilead’s seladelpar gains conditional EU approval for PBC, offering new second-line treatment targeting PPAR Delta with symptom and stiffness benefits.
-
healthSouth Africa Moves to Locally Produce HIV Drug Lenacapavir
South Africa advances plans to locally manufacture lenacapavir, a cutting-edge HIV prevention drug, boosting regional access and health sovereignty.
-
healthGilead Acquires Arcellx for $7.8 Billion to Boost Cancer Therapy Pipeline
Gilead Sciences is acquiring Arcellx for $7.8 billion, aiming to fast-track its CAR-T cancer therapy for multiple myeloma and enhance its technology platform.